News

Wellington currently operates from an 116,000sqft facility that is equipped with process automation equipment and is fully compliant with the latest federal regulations. About 80 employees made the

The two new programs added are expected to address the development of four compounds which target different subpopulations of patients suffering from DMD. To access these new programs,

Eribulin is an investigational anticancer agent discovered and developed by Eisai. Eisai filed simultaneous regulatory applications for approval of Eribulin to the health authorities in the US, Japan

The acceptance letter confirms that the Chemistry, Manufacturing and Controls (CMC) response filed by NexMed is acceptable for the final, 150-day review cycle, during which regulatory reviewers are

Pfizer received approval for the single agent Mylotarg, in the US, under FDA’s accelerated approval regulations based on overall response rate in three non-comparative studies and required submission

Takeda Pharma said that the once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets,

The QL Care Analyzer will be tested utilising CardioGenics’ Troponin-I test, the first in a series of four cardiovascular tests to be offered for use with the QL

As part of the commercialisation agreement, Diamyd holds the right to commercialise the product in the Nordic states. GAD65 is currently being assessed in Phase 3 clinical studies

Dr Arella has more than 30 years of experience as a University professor, and director of a large Research Center for 5 years. Dr Arella also has experience